Regenerative Medical Technology (RMTG) Other Non-Current Liabilities (2021 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Other Non-Current Liabilities of $1.3 million for Q1 2026, up 22545.77% year-over-year from N/an in Q1 2025, and down 45.06% quarter-over-quarter from $2.4 million in Q4 2025.
Regenerative Medical Technology (RMTG) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Regenerative Medical Technology's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 22545.77% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 22545.77% YoY), while the FY2025 annual figure was $2.4 million, up 51223.35% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.3 million, down from $2.4 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $2.4 million in Q4 2025, with the low at $2146.0 in Q4 2023.
- The 5-year median for Other Non-Current Liabilities is $5838.0 (2025), against an average of $224837.9.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities slumped 69.33% in 2023, then soared 51223.35% in 2025.
- Regenerative Medical Technology's Other Non-Current Liabilities stood at $6944.0 in 2022, then tumbled by 69.1% to $2146.0 in 2023, then soared by 118.5% to $4689.0 in 2024, then jumped by 51223.35% to $2.4 million in 2025, then plunged by 45.06% to $1.3 million in 2026.
- Business Quant data shows RMTG's Other Non-Current Liabilities at $1.3 million in Q1 2026, $2.4 million in Q4 2025, and $7029.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.32 Mn |
| Dec 31, 2025 | 2.41 Mn |
| Sep 30, 2025 | 7,029.00 |
| Jun 30, 2025 | 6,166.00 |
| Mar 31, 2025 | 5,838.00 |
| Dec 31, 2024 | 4,689.00 |
| Sep 30, 2024 | 5,574.00 |
| Jun 30, 2024 | 4,352.00 |
| Mar 31, 2024 | 3,644.00 |
| Dec 31, 2023 | 2,146.00 |
| Sep 30, 2023 | 3,055.00 |
| Jun 30, 2023 | 4,019.00 |
| Mar 31, 2023 | 5,017.00 |
| Dec 31, 2022 | 6,944.00 |
| Sep 30, 2022 | 9,960.00 |
| Jun 30, 2022 | 10,836.00 |
| Mar 31, 2022 | 14,363.00 |
| Dec 31, 2021 | 20,442.00 |